间皮瘤-话题@MedSci

#间皮瘤#

67篇内容 | 1848人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2222943, encodeId=091b222294331, content=<a href='/topic/show?id=07a1885eb0' target=_blank style='color:#2F92EE;'>#Hippo#</a> <a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a> <a href='/topic/show?id=5d8e1184e00d' target=_blank style='color:#2F92EE;'>#TEAD#</a>, objectTitle=EMBO Rep：组合使用Hippo 和 MAPK信号通路靶向疗法有望治疗间皮瘤, objectType=article, longId=840970, objectId=c0698409e070, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240828/1724849898288_2185383.png, objectUrl=/article/show_article.do?id=c0698409e070, replyNumber=0, likeNumber=7, createdTime=2024-08-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1579842, encodeId=af6c15e984292, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤, objectType=article, longId=727301, objectId=6669e2730156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6669e2730156, replyNumber=0, likeNumber=60, createdTime=2022-05-20, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6669e2730156, moduleTitle=Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6669e2730156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579841, encodeId=cfbd15e984182, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性, objectType=article, longId=723522, objectId=d134e23522a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d134e23522a2, replyNumber=0, likeNumber=88, createdTime=2022-04-06, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d134e23522a2, moduleTitle=Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d134e23522a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579840, encodeId=dc1f15e9840eb, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Thorax：恶性胸膜和腹膜间皮瘤的发病率、治疗和生存率, objectType=article, longId=295589, objectId=89fd2955899b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89fd2955899b, replyNumber=0, likeNumber=85, createdTime=2022-02-15, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89fd2955899b, moduleTitle=Thorax：恶性胸膜和腹膜间皮瘤的发病率、治疗和生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89fd2955899b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579839, encodeId=9b8815e9839ca, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果, objectType=article, longId=295347, objectId=691929534ef4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=691929534ef4, replyNumber=0, likeNumber=58, createdTime=2022-02-11, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=691929534ef4, moduleTitle=Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=691929534ef4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579838, encodeId=8b1115e983849, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, objectType=article, longId=220461, objectId=b29d2204611e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29d2204611e, replyNumber=0, likeNumber=56, createdTime=2021-11-18, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29d2204611e, moduleTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29d2204611e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579837, encodeId=26b815e98377c, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析, objectType=article, longId=219389, objectId=f5d0219389bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5d0219389bc, replyNumber=0, likeNumber=78, createdTime=2021-10-29, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5d0219389bc, moduleTitle=Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5d0219389bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579836, encodeId=753d15e98361d, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Lancet Oncol：纳武单抗或可成为一线治疗后进展的恶性间皮瘤的新选择！, objectType=article, longId=218904, objectId=c5c4218904d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5c4218904d0, replyNumber=0, likeNumber=63, createdTime=2021-10-21, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5c4218904d0, moduleTitle=Lancet Oncol：纳武单抗或可成为一线治疗后进展的恶性间皮瘤的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5c4218904d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579835, encodeId=1e5315e98352c, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=国内“双免疫”疗法获批！伊匹木单抗联合纳武利尤单抗为恶性胸膜间皮瘤患者带来持久生存获益, objectType=article, longId=218467, objectId=821a21846eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=821a21846eea, replyNumber=0, likeNumber=152, createdTime=2021-10-14, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=821a21846eea, moduleTitle=国内“双免疫”疗法获批！伊匹木单抗联合纳武利尤单抗为恶性胸膜间皮瘤患者带来持久生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=821a21846eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579834, encodeId=f26915e9834e7, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益, objectType=article, longId=217090, objectId=179321e09027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=179321e09027, replyNumber=0, likeNumber=78, createdTime=2021-09-16, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=179321e09027, moduleTitle=CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=179321e09027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579833, encodeId=b25715e983385, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！, objectType=article, longId=216812, objectId=832d216812a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=832d216812a4, replyNumber=0, likeNumber=72, createdTime=2021-09-09, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=832d216812a4, moduleTitle=Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=832d216812a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579832, encodeId=3df815e9832a7, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=JAMA Network Open：全球近30年来间皮瘤发病和死亡持续增长, objectType=article, longId=215741, objectId=a081215e419c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a081215e419c, replyNumber=0, likeNumber=63, createdTime=2021-08-16, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a081215e419c, moduleTitle=JAMA Network Open：全球近30年来间皮瘤发病和死亡持续增长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a081215e419c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579831, encodeId=452615e9831da, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, objectType=article, longId=214989, objectId=b1e72149892f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1e72149892f, replyNumber=0, likeNumber=73, createdTime=2021-07-30, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1e72149892f, moduleTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1e72149892f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579830, encodeId=777515e983086, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=中国恶性胸膜间皮瘤临床诊疗指南（2021版），5分钟get要点！, objectType=article, longId=212767, objectId=e93d212e67f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e93d212e67f4, replyNumber=0, likeNumber=88, createdTime=2021-06-17, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e93d212e67f4, moduleTitle=中国恶性胸膜间皮瘤临床诊疗指南（2021版），5分钟get要点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e93d212e67f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579829, encodeId=612f15e98295d, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=里程碑！免疫“双子星”获国家药品监督管理局批准用于恶性胸膜间皮瘤一线治疗, objectType=article, longId=212620, objectId=76ec212620dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ec212620dd, replyNumber=0, likeNumber=64, createdTime=2021-06-13, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ec212620dd, moduleTitle=里程碑！免疫“双子星”获国家药品监督管理局批准用于恶性胸膜间皮瘤一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ec212620dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579828, encodeId=7a0915e98282e, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Lancet respirat med：派姆单抗单药治疗晚期间皮瘤的疗效分析, objectType=article, longId=209709, objectId=6bf2209e091f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bf2209e091f, replyNumber=0, likeNumber=67, createdTime=2021-04-10, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bf2209e091f, moduleTitle=Lancet respirat med：派姆单抗单药治疗晚期间皮瘤的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bf2209e091f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579827, encodeId=8b6c15e9827f1, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Nat Commun：恶性胸膜间皮瘤的克隆结构可作为预后指标并影响肿瘤微环境, objectType=article, longId=208935, objectId=ef2720893512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef2720893512, replyNumber=0, likeNumber=72, createdTime=2021-03-25, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef2720893512, moduleTitle=Nat Commun：恶性胸膜间皮瘤的克隆结构可作为预后指标并影响肿瘤微环境, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef2720893512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579826, encodeId=7add15e9826a9, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=Lancet Oncol：以放疗后继胸膜外全肺切除术治疗恶性胸膜间皮瘤, objectType=article, longId=205843, objectId=21372058433a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21372058433a, replyNumber=0, likeNumber=68, createdTime=2021-01-20, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21372058433a, moduleTitle=Lancet Oncol：以放疗后继胸膜外全肺切除术治疗恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21372058433a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579825, encodeId=2eec15e982510, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法, objectType=article, longId=201903, objectId=4d5c201903de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d5c201903de, replyNumber=0, likeNumber=82, createdTime=2020-10-11, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d5c201903de, moduleTitle=美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d5c201903de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1579824, encodeId=9ed815e98248e, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, objectTitle=美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者, objectType=article, longId=201898, objectId=555f2018985e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=555f2018985e, replyNumber=0, likeNumber=116, createdTime=2020-10-11, rootId=0, userName=1249884fm92暂无昵称, userId=d61a16562641, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=555f2018985e, moduleTitle=美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555f2018985e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

间皮瘤

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#Hippo# #间皮瘤# #TEAD#

2024-08-29发表于上海

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤

2022-05-20

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性

2022-04-06

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

Thorax：恶性胸膜和腹膜间皮瘤的发病率、治疗和生存率

2022-02-15

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果

2022-02-11

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505

2021-11-18

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析

2021-10-29

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

Lancet Oncol：纳武单抗或可成为一线治疗后进展的恶性间皮瘤的新选择！

2021-10-21

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

国内“双免疫”疗法获批！伊匹木单抗联合纳武利尤单抗为恶性胸膜间皮瘤患者带来持久生存获益

2021-10-14

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益

2021-09-16

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！

2021-09-09

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

JAMA Network Open：全球近30年来间皮瘤发病和死亡持续增长

2021-08-16

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效

2021-07-30

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

中国恶性胸膜间皮瘤临床诊疗指南（2021版），5分钟get要点！

2021-06-17

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

里程碑！免疫“双子星”获国家药品监督管理局批准用于恶性胸膜间皮瘤一线治疗

2021-06-13

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

Lancet respirat med：派姆单抗单药治疗晚期间皮瘤的疗效分析

2021-04-10

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

Nat Commun：恶性胸膜间皮瘤的克隆结构可作为预后指标并影响肿瘤微环境

2021-03-25

一叶知秋 (审核中...)

前往app查看评论内容

#间皮瘤#

Lancet Oncol：以放疗后继胸膜外全肺切除术治疗恶性胸膜间皮瘤

2021-01-20

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法

2020-10-11

1249884fm92暂无昵称 (审核中...)

前往app查看评论内容

#间皮瘤#

美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者

2020-10-11

科室
- - 订阅+
  - 更多科室
工具
服务